- Home
- INZY vs MPAA Comparison
INZY vs MPAA Comparison
Compare INZY & MPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- MPAA
- Stock Information
- Founded
- INZY 2015
- MPAA 1968
- Country
- INZY United States
- MPAA United States
- Employees
- INZY N/A
- MPAA N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- MPAA Auto Parts:O.E.M.
- Sector
- INZY Health Care
- MPAA Consumer Discretionary
- Exchange
- INZY Nasdaq
- MPAA Nasdaq
- Market Cap
- INZY 188.2M
- MPAA 155.8M
- IPO Year
- INZY 2020
- MPAA 1994
- Fundamental
- Price
- INZY $1.36
- MPAA $7.20
- Analyst Decision
- INZY Strong Buy
- MPAA
- Analyst Count
- INZY 8
- MPAA 0
- Target Price
- INZY $17.75
- MPAA N/A
- AVG Volume (30 Days)
- INZY 784.0K
- MPAA 50.6K
- Earning Date
- INZY 03-11-2025
- MPAA 02-07-2025
- Dividend Yield
- INZY N/A
- MPAA N/A
- EPS Growth
- INZY N/A
- MPAA N/A
- EPS
- INZY N/A
- MPAA N/A
- Revenue
- INZY N/A
- MPAA $739,413,000.00
- Revenue This Year
- INZY N/A
- MPAA $8.11
- Revenue Next Year
- INZY N/A
- MPAA $6.48
- P/E Ratio
- INZY N/A
- MPAA N/A
- Revenue Growth
- INZY N/A
- MPAA 5.20
- 52 Week Low
- INZY $1.32
- MPAA $4.36
- 52 Week High
- INZY $7.80
- MPAA $10.40
- Technical
- Relative Strength Index (RSI)
- INZY 20.27
- MPAA 47.93
- Support Level
- INZY $1.32
- MPAA $6.26
- Resistance Level
- INZY $3.18
- MPAA $8.12
- Average True Range (ATR)
- INZY 0.27
- MPAA 0.38
- MACD
- INZY -0.15
- MPAA -0.11
- Stochastic Oscillator
- INZY 2.15
- MPAA 47.96
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About MPAA Motorcar Parts of America Inc.
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts and test solutions and diagnostic equipment. It operate in the non-discretionary automotive aftermarket for replacement hard parts in North America and includes products such as light-duty rotating electrical products, wheel hub products, brake-related products, and turbochargers. In addition, it sell test solutions and diagnostic equipment. The company operates in three segments Hard Parts, Test Solutions and Diagnostic Equipment and Heavy Duty. Key revenue is generated from Hard Parts, which includes (i) light duty rotating electric products such as alternators and starters, (ii) wheel hub products, (iii) brake-related products, including brake calipers, brake boosters, brake rotors.